Kura Oncology (KURA) Operating Leases (2020 - 2026)
Kura Oncology (KURA) posted quarterly Operating Leases of $13.2 million for Q1 2026, up 68.08% year-over-year from $7.9 million in Q1 2025, and up 39.84% quarter-over-quarter from $9.5 million in Q4 2025.
Kura Oncology (KURA) Operating Leases (2020 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Operating Leases for 7 consecutive years, with $13.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases rose 68.08% year-over-year to $13.2 million; the TTM figure through Mar 2026 stood at $13.2 million (up 68.08% YoY), while the FY2025 annual figure was $9.5 million, up 82.45% from the prior year.
- Operating Leases grew to $13.2 million in Q1 2026 per KURA's latest filing, from $9.5 million in the prior quarter.
- Across five years, Operating Leases topped out at $13.2 million in Q1 2026 and bottomed at $1.5 million in Q2 2023.
- Historically, Operating Leases has averaged $5.9 million across 5 years, with a median of $5.8 million in 2024.
- Annual changes were most pronounced in 2023 — Operating Leases plunged 59.61% — and 2024, when it jumped 301.58%.
- Kura Oncology's Operating Leases stood at $2.5 million in 2022, then soared by 149.69% to $6.4 million in 2023, then declined by 18.42% to $5.2 million in 2024, then surged by 82.45% to $9.5 million in 2025, then jumped by 39.84% to $13.2 million in 2026.
- Business Quant data shows KURA's Operating Leases at $13.2 million in Q1 2026, $9.5 million in Q4 2025, and $8.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.37 Mn |
| Mar 31, 2026 | 13.24 Mn |
| Dec 31, 2025 | 9.47 Mn |
| Sep 30, 2025 | 8.36 Mn |
| Jun 30, 2025 | 8.16 Mn |
| Mar 31, 2025 | 7.88 Mn |
| Dec 31, 2024 | 5.19 Mn |
| Sep 30, 2024 | 5.47 Mn |
| Jun 30, 2024 | 5.84 Mn |
| Mar 31, 2024 | 6.23 Mn |
| Dec 31, 2023 | 6.36 Mn |
| Sep 30, 2023 | 6.45 Mn |
| Jun 30, 2023 | 1.46 Mn |
| Mar 31, 2023 | 2.01 Mn |
| Dec 31, 2022 | 2.55 Mn |
| Sep 30, 2022 | 3.08 Mn |
| Jun 30, 2022 | 3.60 Mn |
| Mar 31, 2022 | 4.11 Mn |
| Dec 31, 2021 | 4.61 Mn |
| Sep 30, 2021 | 5.10 Mn |